HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.

AbstractOBJECTIVE:
To determine the efficacy of the interleukin (IL)-1-receptor antagonist (IL-1RA) anakinra in patients with adult-onset Still's disease (AOSD) refractory to standard treatments such as glucocorticosteroids (GC), immunosuppressive drugs, and tumor necrosis factor (TNF)-antagonists; to verify disease remission objectively by serial cytokine measurements; and to review the current literature on anakinra for this indication.
METHODS:
Four patients with AOSD--2 with acute flares of the chronic form of the disease and 2 with intermittent disease--were treated with prednisolone and methotrexate. One was also treated with several other immunosuppressive drugs including etanercept and infliximab. One patient had life-threatening symptoms (toxic megacolon, pneumonitis, disseminated intravascular coagulation) despite high-dose prednisolone. Treatment with anakinra 100 mg/d subcutaneously was initiated. White blood cells (WBC), C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), liver enzymes, ferritin levels, and serum cytokines were analyzed. The current literature on the efficacy of anakinra for AOSD is reviewed.
RESULTS:
Patients with chronic AOSD quickly responded to anakinra treatment (1 day to 3 days). GC could be tapered. ESR, CRP, WBC, ferritin, and liver enzymes returned to normal. Serum cytokine measurements revealed moderately elevated IL-1beta levels and highly elevated IL-18 levels in active disease, which normalized with anakinra. TNF-alpha and IL-6 were moderately elevated only in the 2 patients with chronic AOSD. In the literature, 17 similar cases have been reported to date.
CONCLUSIONS:
Anakinra is effective in treatment-resistant and in life-threatening AOSD. IL-18 serum levels, in addition to CRP, ESR, liver enzymes, ferritin, and WBC, may be helpful in assessing disease activity and response to treatment.
AuthorsIna Kötter, Alexander Wacker, Silvia Koch, Jörg Henes, Constanze Richter, Andreas Engel, Ilhan Günaydin, Lothar Kanz
JournalSeminars in arthritis and rheumatism (Semin Arthritis Rheum) Vol. 37 Issue 3 Pg. 189-97 (Dec 2007) ISSN: 0049-0172 [Print] United States
PMID17583775 (Publication Type: Case Reports, Journal Article, Review)
Chemical References
  • Antirheumatic Agents
  • Cytokines
  • Interleukin 1 Receptor Antagonist Protein
Topics
  • Adult
  • Antirheumatic Agents (therapeutic use)
  • Cytokines (blood)
  • Drug Resistance
  • Female
  • Humans
  • Interleukin 1 Receptor Antagonist Protein (therapeutic use)
  • Male
  • Still's Disease, Adult-Onset (blood, drug therapy, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: